Geode Capital Management LLC Has $6.98 Million Stake in Bioventus Inc. $BVS

Geode Capital Management LLC raised its stake in Bioventus Inc. (NYSE:BVS) by 13.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,054,903 shares of the company’s stock after acquiring an additional 122,137 shares during the period. Geode Capital Management LLC owned about 1.28% of Bioventus worth $6,984,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Bioventus by 35.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,181 shares of the company’s stock worth $157,000 after purchasing an additional 4,513 shares during the last quarter. Mackenzie Financial Corp boosted its position in Bioventus by 27.3% in the first quarter. Mackenzie Financial Corp now owns 41,090 shares of the company’s stock valued at $376,000 after buying an additional 8,824 shares in the last quarter. Vanguard Group Inc. grew its stake in Bioventus by 3.7% during the first quarter. Vanguard Group Inc. now owns 2,554,224 shares of the company’s stock worth $23,371,000 after buying an additional 92,143 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Bioventus by 3.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 448,247 shares of the company’s stock worth $4,101,000 after buying an additional 12,903 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Bioventus by 2.5% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 201,129 shares of the company’s stock worth $1,840,000 after buying an additional 4,950 shares in the last quarter. 62.94% of the stock is owned by institutional investors.

Bioventus Stock Down 7.0%

Shares of BVS opened at $7.09 on Friday. The company has a market capitalization of $586.79 million, a P/E ratio of -11.62 and a beta of 0.79. Bioventus Inc. has a one year low of $5.81 and a one year high of $11.89. The business’s 50 day simple moving average is $7.08 and its 200-day simple moving average is $6.93. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99.

Insider Buying and Selling

In other news, Director Michelle Mcmurry-Heath sold 17,701 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $7.42, for a total transaction of $131,341.42. Following the sale, the director owned 56,997 shares in the company, valued at approximately $422,917.74. This represents a 23.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 33.00% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.